spironolactone has been researched along with Breathlessness in 14 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "BACKGROUND In the setting of acute decompensated heart failure (ADHF), tolvaptan, a selective V₂ receptor antagonist, did not alter plasma renin activity or angiotensin II level, but significantly increased plasma aldosterone by the activation of V₁ₐ receptor, suggesting that a high-dose mineralocorticoid receptor antagonist (MRA) combined with a V₂ receptor antagonist might be of interest, especially in ADHF patients." | 7.91 | Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report. ( Kajimoto, K; Otsubo, S, 2019) |
| "Thirty medically treated ambulatory hypertensive patients (19 women, age 62+/-6 years) with exertional dyspnea, ejection fraction >50%, and diastolic dysfunction (E/A <1, E deceleration time >250 m/sec) and without ischemia were randomized to spironolactone 25 mg/d or placebo for 6 months." | 5.11 | Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. ( Cowley, D; Haluska, B; Leano, R; Marwick, TH; Mottram, PM; Stowasser, M, 2004) |
| "BACKGROUND In the setting of acute decompensated heart failure (ADHF), tolvaptan, a selective V₂ receptor antagonist, did not alter plasma renin activity or angiotensin II level, but significantly increased plasma aldosterone by the activation of V₁ₐ receptor, suggesting that a high-dose mineralocorticoid receptor antagonist (MRA) combined with a V₂ receptor antagonist might be of interest, especially in ADHF patients." | 3.91 | Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report. ( Kajimoto, K; Otsubo, S, 2019) |
| " The ATHENA-HF (Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure) trial is a randomized, double-blind, placebo-controlled study of the safety and efficacy of 100 mg/day spironolactone versus placebo (or continued low-dose spironolactone use in participants who are already receiving spironolactone at baseline) in 360 patients hospitalized for AHF." | 2.82 | Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. ( Anstrom, KJ; Braunwald, E; Butler, J; Felker, GM; Hernandez, AF; Kalogeropoulos, A; Konstam, MA; Redfield, MM; Shah, MR; Tang, WH, 2016) |
| "Chest pain and shortness of breath are chief complaints frequently evaluated in the emergency department." | 1.48 | An uncommon cause of dyspnea in the emergency department. ( Kotora, JG; Schmieler, EJ; St Clair, JW, 2018) |
| "Portopulmonary hypertension is characterized by a chronic liver disease associated with a mean pulmonary artery pressure >25 mmHg at rest, an increased pulmonary vascular resistance and a capillary pulmonary pressure <15 mmHg with portal hypertension." | 1.34 | [Portopulmonary hypertension due to schistosomiasis in two Malagasy patients]. ( Rajaona, HR; Rajaonarivelo, P; Ramanampamonjy, RM; Razafimahefa, SH, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Paulus, R | 1 |
| Schmidt, B | 1 |
| Schmieler, EJ | 1 |
| St Clair, JW | 1 |
| Kotora, JG | 1 |
| Kajimoto, K | 1 |
| Otsubo, S | 1 |
| Wettersten, N | 1 |
| Maisel, AS | 1 |
| Butler, J | 1 |
| Hernandez, AF | 1 |
| Anstrom, KJ | 1 |
| Kalogeropoulos, A | 1 |
| Redfield, MM | 1 |
| Konstam, MA | 1 |
| Tang, WH | 1 |
| Felker, GM | 1 |
| Shah, MR | 1 |
| Braunwald, E | 1 |
| Parker, T | 1 |
| Januzzi, JL | 1 |
| Rehman, S | 1 |
| Mueller, T | 1 |
| van Kimmenade, RR | 1 |
| Lloyd-Jones, DM | 1 |
| Wada, Y | 1 |
| Kobayashi, D | 1 |
| Murakami, S | 1 |
| Oda, M | 1 |
| Hanawa, H | 1 |
| Kuroda, T | 1 |
| Nakano, M | 1 |
| Narita, I | 1 |
| Carrascosa, MF | 1 |
| Larroque, IC | 1 |
| Rivero, JL | 1 |
| García, JA | 1 |
| Hoz, MC | 1 |
| Ares, MA | 1 |
| López, XA | 1 |
| Caviedes, JR | 1 |
| Mottram, PM | 1 |
| Haluska, B | 1 |
| Leano, R | 1 |
| Cowley, D | 1 |
| Stowasser, M | 1 |
| Marwick, TH | 1 |
| Ramanampamonjy, RM | 1 |
| Razafimahefa, SH | 1 |
| Rajaonarivelo, P | 1 |
| Rajaona, HR | 1 |
| Giannarelli, C | 1 |
| De Giorgi, A | 1 |
| De Negri, F | 1 |
| Carmassi, F | 1 |
| Rosen, CA | 1 |
| Thomas, JP | 1 |
| Anderson, D | 1 |
| Kühn, P | 1 |
| Probst, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)[NCT02235077] | Phase 2 | 360 participants (Actual) | Interventional | 2014-12-30 | Completed | ||
| A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer[NCT01708798] | Phase 2/Phase 3 | 44 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to Futility) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Baseline body weight assessment will be completed, and changes in weight documented daily through 96 hours or earlier discharge (NCT02235077)
Timeframe: Randomization through 96 hours or earlier discharge
| Intervention | pounds (Mean) |
|---|---|
| Spironolactone | -8.1 |
| Placebo | -7.5 |
Clinical congestion score will be assessed at randomization, 96 hours, and at discharge. Scale consisted of sum of six signs and symptoms of congestion, each scored 0-3. Zero indicates no sign/symptom and 3 indicates worst case of sign/symptom. Score range 0-18 with 18 being worst score. (NCT02235077)
Timeframe: Randomization through 96 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Spironolactone | -5.59 |
| Placebo | -5.82 |
Dyspnea visual analog scale change from randomization to 96 hours. Scale range 0-100 with 100 being the best possible score. (NCT02235077)
Timeframe: Randomization to 96 hours
| Intervention | units on a scale (Mean) |
|---|---|
| Spironolactone | 17.2 |
| Placebo | 17.9 |
The Core Laboratory at Vermont will determine NT-proBNP levels for calculation of the endpoint from samples obtained at randomization and 96 hours respectively. NT-proBNP was converted to log scale. (NCT02235077)
Timeframe: Randomization to 96 hours
| Intervention | log pg/ml (Mean) |
|---|---|
| Spironolactone | -0.58 |
| Placebo | -0.61 |
Renal function via serum creatinine, will be assessed at randomization and daily through 96 hours (NCT02235077)
Timeframe: Randomization through 96 hours
| Intervention | mg/dl (Mean) |
|---|---|
| Spironolactone | 0.15 |
| Placebo | 0.16 |
Change in serum potassium levels at 96 hours as compared to baseline. (NCT02235077)
Timeframe: Baseline, 96 hours
| Intervention | mEq/L (Mean) |
|---|---|
| Spironolactone | 0.31 |
| Placebo | 0.15 |
Fluid intake and urine output will be assessed daily while in hospital through 96 hours. Net fluid output (output minus input) through 96 hours is reported. (NCT02235077)
Timeframe: Randomization through 96 hours
| Intervention | ml (Mean) |
|---|---|
| Spironolactone | 5824 |
| Placebo | 5507 |
Medications will be reviewed to assess loop diuretic dose requirements through Day 30 following randomization (NCT02235077)
Timeframe: Randomization through Day 30
| Intervention | mg (Mean) |
|---|---|
| Spironolactone | 19.66 |
| Placebo | 30.70 |
All participants will be contacted by telephone at 60 days, +/- 3 days post randomization to assess vital status (death). (NCT02235077)
Timeframe: 60 days post randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Spironolactone | 8 |
| Placebo | 10 |
Outpatient worsening heart failure symptoms will be assessed from discharge through Day 30 (NCT02235077)
Timeframe: Hospital discharge through Day 30
| Intervention | Participants (Count of Participants) |
|---|---|
| Spironolactone | 19 |
| Placebo | 17 |
1 review available for spironolactone and Breathlessness
| Article | Year |
|---|---|
Biomarkers for Heart Failure: An Update for Practitioners of Internal Medicine.
Topics: Adrenergic beta-Antagonists; Aged; Biomarkers; Calcitonin; Comorbidity; Diagnosis, Differential; Diu | 2016 |
2 trials available for spironolactone and Breathlessness
| Article | Year |
|---|---|
Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
Topics: Acute Disease; Cause of Death; Disease Progression; Double-Blind Method; Dyspnea; Heart Failure; Hum | 2016 |
Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.
Topics: Aged; Aorta; Compliance; Diastole; Dyspnea; Exercise Test; Exercise Tolerance; Female; Heart Atria; | 2004 |
11 other studies available for spironolactone and Breathlessness
| Article | Year |
|---|---|
90-year-old man • dyspnea • lower extremity edema • limitations in daily activities • Dx?
Topics: Activities of Daily Living; Aged, 80 and over; Diagnosis, Differential; Diuretics; Dyspnea; Edema; F | 2020 |
An uncommon cause of dyspnea in the emergency department.
Topics: Adult; Chest Pain; Computed Tomography Angiography; Diagnosis, Differential; Dyspnea; Electrocardiog | 2018 |
Adding High-Dose Spironolactone to Tolvaptan Improves Acute Decompensated Heart Failure Due to Obstructive Hypertrophic Cardiomyopathy and Aortic Stenosis: A Case Report.
Topics: Acute Disease; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Aortic Valve Stenosis; | 2019 |
Case of the month. Idiopathic dilated cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Angiography; Angiotensin-Converting | 2009 |
Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients.
Topics: Acute Disease; Biomarkers; Cohort Studies; Diuretics; Dyspnea; Female; Humans; Interleukin-1 Recepto | 2010 |
Cardiac AA amyloidosis in a patient with rheumatoid arthritis and systemic sclerosis: the therapeutic potential of biological reagents.
Topics: Aged; Amyloidosis; Antibodies, Antinuclear; Antirheumatic Agents; Arthritis, Rheumatoid; Benzimidazo | 2011 |
Pulmonary arterial hypertension associated with neurofibromatosis type 1.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Diuretics; Dyspnea; Fatal Outcome; Female; Follow-U | 2010 |
[Portopulmonary hypertension due to schistosomiasis in two Malagasy patients].
Topics: Adolescent; Adult; Anthelmintics; Ascites; Combined Modality Therapy; Diet, Sodium-Restricted; Dyspn | 2007 |
Decompensated porto-pulmonary hypertension in a cirrhotic patient with thrombosis of portocaval shunt.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diet, Sodium-Restricted; Di | 2007 |
Bilateral vocal fold paralysis caused by familial hypokalemic periodic paralysis.
Topics: Adult; Diuretics; Dyspnea; Exercise Test; Female; Humans; Hypokalemia; Paralyses, Familial Periodic; | 1999 |
[Acid-base equilibrium and blood gas analysis in clinical cardiology].
Topics: Acetazolamide; Acid-Base Equilibrium; Bicarbonates; Blood Gas Analysis; Body Weight; Diagnosis, Diff | 1970 |